Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederpubmed.ncbi.nlm.nih.gov
Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat]
Get the latest updates from Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat] directly as they happen.
Follow now 166 followers
Latest posts
Last updated 15 days ago
A Multifactorial Model to Predict the Surgical Complexity of Lung Resection After Neoadjuvant Chemoimmunotherapy
15 days ago
Ann Thorac Surg Short Rep. 2025 Oct 16;4(1):224-228. doi: 10.1016/j.atssr.2025.09.014. eCollection 2026...
Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC
about 2 months ago
JTO Clin Res Rep. 2025 Nov 20;7(4):100933. doi: 10.1016/j.jtocrr.2025.100933. eCollection 2026 Apr.ABSTRACTTarlatamab...
What can we expect from a combination of datopotamab deruxtecan, carboplatin, and pembrolizumab for brain metastases from non-small cell lung cancer?
2 months ago
Expert Opin Emerg Drugs. 2025 Dec;30(4):221-223. doi: 10.1080/14728214.2026.2643169. Epub 2026 Mar 30.NO...
Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study
2 months ago
JTO Clin Res Rep. 2025 Oct 29;7(3):100926. doi: 10.1016/j.jtocrr.2025.100926. eCollection 2026 Mar.ABSTRACTINTRODUCTION...
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database
3 months ago
Lung Cancer. 2025 Oct 20;214:108801. doi: 10.1016/j.lungcan.2025.108801. Online ahead of print.ABSTRACTOBJECTIVES: Tarlatamab...
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naive locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
3 months ago
Front Oncol. 2026 Jan 26;15:1721624. doi: 10.3389/fonc.2025.1721624. eCollection 2025.ABSTRACTBACKGROUND: Immunotherapy targeting the...
A comprehensive clinical trajectory of EGFR A763_Y764insFQEA-positive non-small cell lung cancer treated with fifth-line osimertinib following circulating tumor DNA-based detection: a case report
3 months ago
Transl Lung Cancer Res. 2026 Jan 31;15(1):21. doi: 10.21037/tlcr-2025-869. Epub 2025 Dec...
Data mining and toxicity profile analysis of immune checkpoint inhibitor-related skin toxicity events based on FAERS
3 months ago
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025 Nov 28;50(11):1990-2002...
Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study
3 months ago
JTO Clin Res Rep. 2025 Dec 12;7(2):100940. doi: 10.1016/j.jtocrr.2025.100940. eCollection 2026 Feb.ABSTRACTINTRODUCTION...
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following
3 months ago
ESMO Real World Data Digit Oncol. 2025 May 20;8:100152. doi: 10.1016/j.esmorw.2025.100152. eCollection...
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study
3 months ago
ESMO Real World Data Digit Oncol. 2025 Apr 14;8:100137. doi: 10.1016/j.esmorw.2025.100137. eCollection...
Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report
3 months ago
Case Rep Oncol. 2025 Dec 18;19(1):218-223. doi: 10.1159/000550082. eCollection 2026 Jan-Dec.ABSTRACTINTRODUCTION: Tarlatamab...